Recent Updates
Recently added Catalysts
ZLAB

argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

Tuesday, March 2, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer

Full Press Release Details

argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis.
ShareAdd on Google
Tags: ZLAB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 2, 2021

Biotech snapshot

Cash runway
$618M liquidity · $21M/mo burn
~28 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Small-cell Lung Cancer →

Catalyst track record

+60%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →